ESGV vs XBI
Vanguard ESG US Stock ETF vs SPDR S&P Biotech ETF
- • ESGV has the lower expense ratio at 0.09% vs 0.35% for XBI.
- • ESGV pays a higher dividend yield (0.90%).
Side-by-side metrics
| Metric | ESGV | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.09% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.90% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $13.04B | $10.92B |
YTD return | 10.67% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.11 | 1.01 |
P/E ratio | 24.03 | — |
Last price | $134.43 | $156.41 |
Inception | — | — |
Issuer | Vanguard | State Street |
ESGV top holdings
| NVDA | NVIDIA Corp | 8.92% |
| AAPL | Apple Inc | 8.06% |
| MSFT | Microsoft Corp | 6.38% |
| AMZN | Amazon.com Inc | 4.05% |
| GOOGL | Alphabet Inc Class A | 3.35% |
| AVGO | Broadcom Inc | 2.73% |
| GOOG | Alphabet Inc Class C | 2.71% |
| META | Meta Platforms Inc Class A | 2.67% |
| MU | Micron Technology Inc | 2.01% |
| TSLA | Tesla Inc | 1.73% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About ESGV
ESGV (Vanguard ESG US Stock ETF) is Broad US market with ESG screens applied. Managed by Vanguard, the fund carries $13.0B in assets under management, an expense ratio of 0.09%, a dividend yield of 0.90%. Its largest holding is NVIDIA Corp (NVDA), which represents 8.9% of the portfolio. Real Estate is the fund's largest sector exposure at 2.5%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.